< Zurück zu den aktuellen Neuigkeiten & Events

Neuigkeiten

Patent filings reveal companies embracing microalgae for sustainable foods

November 2020

This week, food giant Unilever announced a €1bn annual sales target for plant-based foods within the next 5-7 years, as part of its “Future Foods” program. This ambitious target is expected to be driven by sales under The Vegetarian Butcher brand, as well as vegan varieties of Ben & Jerry’s, Wall’s, Hellman’s and Magnum.

So, what will be the source of the plant-based fats and proteins needed to support this growth? Vegan Magnums contain pea protein and coconut oil, non-dairy Ben & Jerry’s is made using almond milk, while vegan Cornettos and products in The Vegan Butcher range are based on soy. However, given some of the environmental issues posed by dairy alternatives, such as the high water consumption of almond plants, how sustainable is long-term growth based on these types of proteins?

Unilever is obviously already considering the sustainability of its plant-based offerings, having recently partnered with UK-based algal biotechnology firm Algenuity. The founders of Algenuity have filed an international patent application (published as WO2020/105001) directed to a modified strain of Chlorella vulgaris having a reduced chlorophyll content, and a composition comprising an algae biomass derived from the modified strain. The reduction in chlorophyll is said to overcome the problem of the strong colour, taste and smell normally associated with this microalgal species, making it more suitable for use in foods. Two further applications were filed earlier this year in the UK for modified strains of Chlorella vulgaris.

Microalgae are microscopic, unicellular organisms which convert CO2 into useful nutrients. Given their low carbon footprint and ability to be cultured to a high density, microalgae have gained considerable interest for use in biofuels, cosmetics, pharmaceuticals and as food ingredients, with the global microalgae market estimated to exceed 75 million USD by 2027*.

It is therefore unsurprising that Unilever isn’t the only corporate giant which has recognised the potential of microalgae, and the patent literature reveals other key players taking an interest in the microalgae market. Glaxosmithkline Biologicals has filed a patent application (WO2020/178720), jointly with Washington University, for a nutraceutical composition which may comprise spirulina (microalgae of the Arthospira genus), for improving health and boosting the immune system. Mitsubishi-backed Japanese start-up Tavelmout Corporation is also focussing on mass-produced spirulina as a source of sustainable protein. Like Algenuity, the company seeks to provide foods and beverages which don’t suffer from the characteristic taste and smell of algae, and its pending patent (WO2019/102732) is directed to a culturing process which comprises a decolouration step. Of course, the benefits of microalgae are not limited to foods for human consumption; Mars is seeking patent protection (WO2018/125631) for the use of algal biomass to replace animal plasma as a pet food binder.

As well as an increase in patent filings for microalgae-based products and process in the food tech field, the next few years will likely see more collaborations between big corporates and smaller biotech firms or universities who have specialised knowledge of microalgal strains and culture conditions. This know-how is another valuable source of IP, since the ability to efficiently scale-up microalgae production and incorporate biomass into food compositions while retaining desirable taste and textural properties will be critical to the success of new products. Companies who optimise their IP strategy so as to protect key innovations and strains through patents, while also being able to offer their know-how in collaborations with food giants, will be best placed to capitalize in this growing field.

*Data Bridge Market Research

This article was prepared by HGF Patent Director Dr Jennifer Bailey. If you would like further advice on this or any other matter, please contact Jennifer.  Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Aktuelle Neuigkeiten

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it? This case centres on the evidence required to …

Weiterlesen

IAM Global Leaders 2026

HGF is proud to announce that we have 3 partners listed as an IAM Global Leader 2026. To qualify for inclusion in the IAM Global Leaders, individuals must be ranked …

Weiterlesen

The Bite of Implied Consent: Lessons from the Pink Lady Case

A recent European Union court decision considers the issue of implied consent to commercialise a plant variety, and whether the evidence meets the threshold of “serious doubts” of the validity …

Weiterlesen
Event - 5. November 2025

HGF are Gold Sponsors of IAM Live: Navigating the UPC 2025

We’re excited to share that HGF is a Gold Sponsor of IAM Live: Navigating the UPC 2025, taking place on the 5th November at the Marriott Opera Ambassador Hotel in …

Veranstaltungsdetails

HGF ranked band 1 in Chambers and Partners UK 2026

The Chambers and Partners UK 2026 Guide is now live and HGF has one again been highly ranked as a firm, with several recognised individuals across multiple regions. HGF is …

Weiterlesen

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Weiterlesen
Event - 14. Oktober 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Veranstaltungsdetails

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Weiterlesen